aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 9.52 percent decrease over losses of $(0.42) per share from the same period last year.
Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $401
Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $399 to $401.
